> Concomitant usage of inebilizumab with IMMUNOSUPPRESSANTS, including systemic CORTICOSTEROIDS, may increase the risk of infection. The effects of inebilizumab on B cells and IMMUNOGLOBULINS may persist for 6 months or longer following its administration. 
